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In the field of antitumor drug development, it is common to 
see paired images of cultured cancer cells: one mock-  
treated, and the other subjected to a small molecular drug 
that leads to cell death or growth suppression (Figure 1). 
One’s common perception is that an inhibitor is at work to 
inactivate a critical factor or pathway essential for cancer 
cell survival. In the August issue of Cancer Cell [1], how-
ever, a team of researchers from Baylor College of Medi-
cine led by Dr. Bert O’Malley described a completely op-
posite path for the annihilation of tumors. Instead of using 
drugs to inhibit the oncogene targets, they used an activator 
molecule to overstimulate them. The apparent effectiveness 
and selectiveness of cancer cell killing are astounding.     
The pursuit of targeted cancer therapy began more than 
20 years ago. The main strategy is to seek out targets that 
are vital for cancer cell homeostasis and derive biological or 
small molecule drugs to suppress the function of the targets. 
The explosion of “nib” and “mab” drugs in the past decade 
is a direct testament to the success of this strategy. Inhibi-
tory modalities have seen unprecedented efficacies in treat-
ing many types of cancers over conventional chemotherapy, 
with substantially reduced systematic adversities. From the 
widely used Trastuzumab/Herceptin [2] in treating breast 
and GI cancers to the recent success of Ibrutinib that scored 
a frontal response as high as 68% in mantle cell lymphoma 
patients [3], oncogene inhibitors have been the driving force 
for individualized cancer treatment. However, the target 
inhibition theme of drug discovery has obvious limitations. 
In many cases, cancer cells can quickly switch to alternative 
pathways to evade the drug. Certain highly activated onco-
genic pathways are difficult to find effective inhibitors. 
Many oncogenes are deemed “undruggable” for lacking 
structurally defined catalytic or ligand binding domains. 
Therefore, overstimulating an oncogenic pathway to disrupt 
cancer cell homeostasis is a conceptual advance that calls 
for the oncogenic targets to be explored from a brand new 
angle. 
The steroid receptor coactivator (SRC) family of three 
proteins, SRC-1, -2, and -3, plays a key role in bridging 
nuclear receptors and other transcription factors to stimulate 
gene transcription of proteins necessary for the fast prolifer-
ation of cancer cells. The expression level and activity of 
SRCs are elevated in many types of cancer, including 
breast, endometrial, ovarian, prostate, and GI tumors. Work 
from the Baylor team began with systematic drug screens 
against the SRCs. Because the drug screen readout allowed 
both inhibitors and activators to be identified, they identi-
fied a cyclohexanone-based molecule MCB-613 that exhib-
its profound potency in overstimulating all three SRCs. 
Validating the in vivo effect of MCB-613 indicated that this 
drug has a strong selectivity in killing cancer cells while 
sparing primary hepatocytes and embryonic fibroblasts 
where SRCs are not overexpressed. Examination of 
MCB-613-mediated cell death revealed paraptotic-like 
characteristics such as excessive vacuolization. Consistent-
ly, molecular analyses indicated ER stress-induced unfolded 
protein response and markedly increased ROS amplitude. 
These results suggest that hyperactivation of the SRCs and 
the resulting overproduction of proteins, among the other 
effects, further exacerbate the high level of protein folding  
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Figure 1  MCB-613 induces complex cytotoxicity with characteristics of 
paraptotic-like cell death. Extensive cytoplasmic vacuolization in the indi-
cated cancer cell lines treated with MCB-613. Scale bar, 20 m. Adapted 
from Wang et al. [3] with permission from the authors. 
stress and oxidative stress in cancer cells beyond the tolera-
ble threshold. It now becomes evident that the high meta-
bolic stress in fast proliferating cancer cells is yet another 
vulnerability that can be explored for cancer therapeutics. 
Most tumor cells are addictive in one form or the other to 
transcription-activating oncogenes that fuel the high de- 
mand for proteins. Some are already at the verge of maxi-
mum capacity in dealing with the oxidative stress and un-
folded proteins associated with high levels of protein pro-
duction. Normal cells, on the other hand, are well within the 
threshold of ER and oxidative stress. Overstimulation of 
oncogenes that are not overexpressed in normal cells will be 
less likely to yield detrimental impact. Thus, the oncogene 
hyperactivation strategy may gain its tumor selectivity by 
distinguishing between cell stress levels, which can be ad-
vantageous since many biomarkers for ER stress, oxidative 
stress, and UPR are well established at the cellular level. 
In summary, overstimulation of oncogenic transcription 
machineries is in many ways akin to overdosing a drug ad-
diction, which can be simultaneously potent and selective. It 
also drastically expands the list of druggable oncogene tar-
gets. The prospect of cancer drugs designed for overstimu-
lating oncogenic targets is a fascinating endeavor awaiting 
future clinical proof of principal. 
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